Patents by Inventor Shilpa Sambashivan

Shilpa Sambashivan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyridine derivatives as SARM1 inhibitors
    Patent number: 11970481
    Abstract: This disclosure is drawn to substituted pyridine compounds and compositions, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing a neurological diseases.
    Type: Grant
    Filed: October 4, 2023
    Date of Patent: April 30, 2024
    Assignee: NURA BIO, INC.
    Inventors: Jennifer Aiden Kozak, Sean Pomeroy Brown, Christopher Michael Tegley, Alexander Wayne Schammel, Liusheng Zhu, Maximiliano De La Higuera Macias, Shilpa Sambashivan
  • SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS
    Publication number: 20240116901
    Abstract: This disclosure is drawn to substituted pyridine compounds and compositions, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing a neurological diseases.
    Type: Application
    Filed: October 4, 2023
    Publication date: April 11, 2024
    Inventors: Jennifer Aiden KOZAK, Sean Pomeroy BROWN, Christopher Michael TEGLEY, Alexander Wayne SCHAMMEL, Liusheng ZHU, Maximiliano DE LA HIGUERA MACIAS, Shilpa SAMBASHIVAN
  • Substituted pyridine derivatives as SARM1 inhibitors
    Patent number: 11945796
    Abstract: This disclosure is drawn to substituted pyridine compounds and compositions, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing neurological diseases.
    Type: Grant
    Filed: September 15, 2021
    Date of Patent: April 2, 2024
    Assignee: NURA BIO, INC.
    Inventors: Sean Pomeroy Brown, Keira Garland, Shilpa Sambashivan, Christopher Michael Tegley, Liusheng Zhu
  • SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS
    Publication number: 20230339913
    Abstract: This disclosure is drawn to substituted pyridine compounds and compositions, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing a neurological diseases.
    Type: Application
    Filed: August 3, 2021
    Publication date: October 26, 2023
    Inventors: Jennifer Aiden KOZAK, Sean Pomeroy BROWN, Michael Christopher TEGLEY, Alexander Wayne SCHAMMEL, Liusheng ZHU, Maximiliano DE LA HIGUERA MACIAS, Shilpa SAMBASHIVAN
  • TREM2 ANTIGEN BINDING PROTEINS AND USES THEREOF
    Publication number: 20220204611
    Abstract: The present invention relates to antigen binding proteins, such as monoclonal antibodies, that specifically bind to and activate human triggering receptor expressed on myeloid cells-2 (TREM2) and pharmaceutical compositions comprising such antigen binding proteins. The agonist antigen binding proteins (e.g. antibodies) of the invention are capable of activating TREM2/DAP12 signaling in myeloid cells in the absence of Fc-mediated cross-linking of the antigen binding proteins. Methods of treating or preventing conditions associated with TREM2 loss of function, such as Alzheimer's disease and multiple sclerosis, using the antigen binding proteins are also described.
    Type: Application
    Filed: September 28, 2021
    Publication date: June 30, 2022
    Inventors: Ian N. FOLTZ, Shilpa SAMBASHIVAN, Irwin CHEN, Susie Miki HARRIS, Dora TOLEDO WARSHAVIAK, Ian DRIVER, Daniel LU
  • SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS
    Publication number: 20220081417
    Abstract: This disclosure is drawn to substituted pyridine compounds and compositions, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing neurological diseases.
    Type: Application
    Filed: September 15, 2021
    Publication date: March 17, 2022
    Inventors: Sean Pomeroy Brown, Keira Garland, Shilpa Sambashivan, Christopher Michael Tegley, Liusheng Zhu
  • Anti-human TREM2 antibodies and uses thereof
    Patent number: 11186636
    Abstract: The present invention relates to antigen binding proteins, such as monoclonal antibodies, that specifically bind to and activate human triggering receptor expressed on myeloid cells-2 (TREM2) and pharmaceutical compositions comprising such antigen binding proteins. The agonist antigen binding proteins (e.g. antibodies) of the invention are capable of activating TREM2/DAP12 signaling in myeloid cells in the absence of Fc-mediated cross-linking of the antigen binding proteins. Methods of treating or preventing conditions associated with TREM2 loss of function, such as Alzheimer's disease and multiple sclerosis, using the antigen binding proteins are also described.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: November 30, 2021
    Assignee: AMGEN INC.
    Inventors: Ian Foltz, Shilpa Sambashivan, Irwin Chen, Susie Miki Harris, Dora Toledo Warshaviak, Ian Driver, Daniel Lu
  • TREM2 Antigen Binding Proteins And Uses Thereof
    Publication number: 20210054069
    Abstract: The present invention relates to antigen binding proteins, such as monoclonal antibodies, that specifically bind to and activate human triggering receptor expressed on myeloid cells-2 (TREM2) and pharmaceutical compositions comprising such antigen binding proteins. The agonist antigen binding proteins (e.g. antibodies) of the invention are capable of activating TREM2/DAP12 signaling in myeloid cells in the absence of Fc-mediated cross-linking of the antigen binding proteins. Methods of treating or preventing conditions associated with TREM2 loss of function, such as Alzheimer's disease and multiple sclerosis, using the antigen binding proteins are also described.
    Type: Application
    Filed: April 20, 2018
    Publication date: February 25, 2021
    Applicant: AMGEN INC.
    Inventors: Ian Foltz, Shilpa Sambashivan, Irwin Chen, Susie Miki Harris, Dora Toledo Warshaviak, Ian Driver, Daniel Lu